EQRx, Inc.
EQRXW
NASDAQ Global Market0.05
USD
- -
- -
CIK
0001843762
CUSIP
26886C115
Return %
Stock
S&P500
1Y
- -
18.99
3Y
-93.50
64.75
5Y
-97.44
71.84
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Alexis A. Borisy A.M.
- Full Time Employees
- 216
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 50 Hampshire Street Cambridge MA United States of America 02139
- IPO Date
- Dec 20, 2021
- CIK
- 0001843762
- Website
- eqrx.com
- Similar Companies
- Business
- EQRx, Inc. (Ticker: EQRXW) is a clinical-stage biopharmaceutical company focused on developing innovative medicines for oncology and immune-inflammatory diseases. Founded in 2019 and headquartered in Cambridge, Massachusetts, the company previously advanced a pipeline including aumolertinib, an EGFR inhibitor for EGFR-mutated non-small cell lung cancer; sugemalimab, an anti-PD-L1 antibody for stage III and IV NSCLC; lerociclib (EQ132), a CDK4/6 inhibitor; nofazinlimab (EQ176), an anti-PD-1 antibody for primary liver cancer; and EQ121, a JAK-1 inhibitor, alongside preclinical programs in partnership with entities such as AbCellera, Absci, and Evotec. Prior to its acquisition, EQRx reset its strategy in May 2023 to prioritize clinically differentiated assets like lerociclib while streamlining operations and leveraging a $1.3 billion cash position. In November 2023, Revolution Medicines, Inc. completed an all-stock acquisition of EQRx, adding over $1 billion in net cash to the acquirer's balance sheet; EQRx's programs were subsequently wound down, with intellectual property returned to partners, and its shares converted at a ratio of 0.1112 shares of Revolution Medicines common stock per EQRx share, resulting in delisting from Nasdaq.